BillionToOne wins bullish backing, but Jefferies and Wells Fargo urge caution

Investing.com -- BillionToOne received a wave of upbeat Wall Street initiations as analysts highlighted the company’s proprietary DNA detection technology and early traction in prenatal and oncology testing.

But two firms struck a more cautious tone on valuation.

Piper Sandler and JPMorgan both launched coverage with Overweight ratings and $150 price targets, pointing to the company’s ability to detect genetic material at extremely low concentrations.

Piper Sandler’s David Westenberg said BillionToOne “built a platform to capture targeted molecules at single count levels and remove artifacts before amplification,” enabling what he called “leading error correction technology.”

He said this approach should support “a 25%+ revenue CAGR in reproductive health,” with oncologists suggesting its tumour-focused testing could be “game-changing.”

JPMorgan analyst Casey Woodring echoed the bullish outlook, saying BLLN’s smNGS platform allows direct fetal risk assessment and “provides therapy selection insights and real-time monitoring of patient response.”

He projected a 29% revenue CAGR from 2025 to 2030 and said a competitive tissue-free MRD test expected in 2026 supports further growth. Despite the stock’s 117% year-to-date rally, Woodring said he “likes the set up for the stock over time.”

Stifel also initiated at Buy with a $145 target. Analyst Daniel Arias said the company is taking share in non-invasive prenatal testing thanks to “meaningful performance and workflow advantages,” adding that early oncology volumes “look promising” and that BLLN is already profitable “in a way that peers won’t be for years.”

Meanwhile, Jefferies urged restraint. Analyst Tycho Peterson initiated with a Hold and a $117 target, noting shares had doubled since the IPO.

He said the company’s highly sensitive assays support “outsized growth (>40% CAGR through ’28)” but added that the stock already trades at “12x ’26 sales.”

Elsewhere, Wells Fargo was also more cautious, initiating the stock with an Equal Weight rating and $110 price target, telling investors that “ BLLN now trades at a substantial premium vs. peers.”

You May Also Be Interested In

• Sovereign debt plummets as inflation fears push yields to multi-year peaks
• Exclusive: IBM Ventures backs physics acceleration firm BQP as bookings climb 8x
• Google launches Gemini 3.8 Flash Cyber for government security